The only hormone tesamorelin was proven to change is IGF-1, which rose about 81% in its approval trial. Testosterone was never an endpoint. The one axis interaction with real support runs backward: testosterone modestly raises IGF-1, not the reverse.
No. Tesamorelin does not directly raise testosterone. It is a GHRH analog that stimulates the pituitary to release growth hormone, which acts on the GH axis. Testosterone is produced on the gonadal axis, a separate hormonal system with its own control loop. Tesamorelin is FDA-approved only for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy [2], and testosterone is not among the hormones it targets.
- Tesamorelin acts on the GH axis, not the gonadal axis that makes testosterone
- It is FDA-approved only for HIV-associated lipodystrophy; testosterone is not an outcome it targets [2]
- A 26-week RCT of growth hormone itself found no change in total or free testosterone, or LH [1]
- Its measured hormonal effect is on IGF-1, which rose about 81% in trials [3]
- The one interaction with support runs the other way: testosterone modestly raises IGF-1 [5][6]
Two Separate Hormonal Axes
The GH axis runs from hypothalamic GHRH to the pituitary to growth hormone to liver IGF-1. Tesamorelin is a stabilized 44-amino-acid GHRH analog that enters at the top of this chain and stimulates the pituitary to release its own GH [2]. The gonadal axis runs from GnRH to the pituitary hormones LH and FSH to testicular testosterone. Different releasing hormones, different pituitary cell populations, different target organs.
The two axes share the pituitary as a junction, which is where the confusion starts. A GHRH signal drives the somatotroph cells that make GH. It does not drive the gonadotroph cells that make LH. Stimulating GH release does not stimulate testosterone release.
What Tesamorelin Actually Changes
Tesamorelin's measured endocrine effect is on IGF-1, not testosterone. In its phase 3 trial, IGF-1 rose about 81% while visceral fat fell about 15% over 26 weeks [3]. Testosterone was not an endpoint, and the approved labeling describes the drug's action as growth hormone release, not androgen production [2].
The clearest test of whether GH-axis stimulation touches testosterone used growth hormone directly. In a 26-week randomized placebo-controlled trial in adults aged 65 to 88, GH normalized IGF-1 but produced no significant change in total or free testosterone in either sex, and no change in luteinizing hormone [1]. Tesamorelin works one step upstream of GH, so it is not plausible that it raises testosterone when GH itself did not.
A review of GH effects on the adult human gonads reaches the same place. It reports that testosterone levels in GH-deficient patients remained unaltered after GH treatment [4].
Tesamorelin Is Not Testosterone Therapy
This distinction matters clinically because the two treatments answer different complaints. Low testosterone shows up as low libido, erectile changes, loss of morning erections, mood change, and loss of muscle. Testosterone replacement treats that directly by restoring serum testosterone to a target range.
Tesamorelin does none of that. If a man's real problem is hypogonadism, a GH-axis peptide will not fix it, and starting one instead of evaluating testosterone delays the correct workup. The gonadal axis deserves its own evaluation, including total testosterone, free testosterone, LH, and FSH.
A program that offers tesamorelin or sermorelin as a fix for low testosterone symptoms is treating the wrong axis. Ask for an LH and FSH draw before accepting that framing.
The Interaction That Does Exist Runs Backward
There is a real link between these systems, and it points the opposite way from the marketing. Testosterone modestly raises IGF-1, not the reverse. In men aged 65 and over with low testosterone, transdermal testosterone raised GH pulse frequency and increased IGF-1 by about 15.3 ng/mL [5], an effect the authors attribute to aromatization of testosterone to estradiol.
An earlier crossover study in normal men found testosterone enanthate raised IGF-1 while nandrolone did not [6]. So if anything, treating low testosterone can nudge the GH axis upward. Treating the GH axis does not return the favor.
Treating Both Axes Together
When both axes are genuinely deficient, treating both is reasonable and the effects are additive rather than redundant. In a factorial trial in older men, lean mass rose 1.6 kg with testosterone alone and 3.0 kg with testosterone plus growth hormone, while strength rose 23% and 35% [7].
Two honest caveats. That trial used recombinant GH, not tesamorelin or sermorelin, and no combined testosterone plus GHRH-analog outcome trial exists. The combination also raised systolic blood pressure by 12 mmHg and hematocrit by 2.0% [7], so it calls for monitoring rather than enthusiasm. If you compete in tested sport, note that tesamorelin and all GHRH analogs are on the 2026 WADA Prohibited List at all times [8].
Tesamorelin works on the GH axis and will not raise testosterone. If your symptoms point to low T, PeterMD runs testosterone therapy with a physician evaluation and follow-up labs, and offers GH-axis peptides separately for the goals those actually address.
Bottom Line
Frequently Asked Questions
Does tesamorelin increase testosterone?
No. Tesamorelin is a GHRH analog that stimulates growth hormone on the GH axis, which is separate from the gonadal axis that produces testosterone [2]. The most direct test used growth hormone itself: a 26-week randomized trial found no change in total or free testosterone or luteinizing hormone [1]. Tesamorelin acts one step upstream of GH, so it does not raise testosterone.
Will tesamorelin help with low testosterone symptoms?
No. If low libido, erectile changes, or loss of muscle trace to low testosterone, tesamorelin does not treat that. It changes IGF-1, not testosterone [3]. Low testosterone needs a gonadal-axis evaluation with total and free testosterone plus LH and FSH, and testosterone replacement if it is confirmed.
Does tesamorelin lower testosterone?
There is no evidence it meaningfully lowers testosterone either. It acts on the GH axis, and a 26-week growth hormone trial found no change in either direction for total or free testosterone [1]. A review of GH effects on the gonads similarly found testosterone unaltered after GH treatment [4].
Does testosterone raise IGF-1?
Yes, modestly, and this is the direction with real support. In older men with low testosterone, transdermal testosterone raised GH pulse frequency and increased IGF-1 by about 15.3 ng/mL, attributed to aromatization to estradiol [5]. In normal men, testosterone enanthate raised IGF-1 while nandrolone did not [6]. The GH axis does not raise testosterone in return.
Can I take tesamorelin and testosterone together?
When both axes are genuinely deficient, the effects are additive: a factorial trial found lean mass rose 1.6 kg with testosterone alone versus 3.0 kg with testosterone plus growth hormone [7]. That trial used recombinant GH, not tesamorelin, and no combined tesamorelin plus testosterone trial exists. The combination raised systolic blood pressure 12 mmHg and hematocrit 2.0% [7], so it needs monitoring.
References
- Effects of growth hormone administration on luteinizing hormone secretion in healthy older men and women Physiological Reports, 2017. PMID: 29208686. https://pubmed.ncbi.nlm.nih.gov/29208686/
- EGRIFTA SV (tesamorelin) for injection, for subcutaneous use: full prescribing information DailyMed, U.S. National Library of Medicine, 2010. Initial U.S. Approval: 2010. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224
- Metabolic effects of a growth hormone-releasing factor in patients with HIV New England Journal of Medicine, 2007. PMID: 18057338. https://pubmed.ncbi.nlm.nih.gov/18057338/
- Effects of growth hormone on adult human gonads: action on reproduction and sexual function International Journal of Endocrinology, 2023. PMID: 37064267. https://pubmed.ncbi.nlm.nih.gov/37064267/
- Effects of transdermal testosterone gel or an aromatase inhibitor on serum concentration and pulsatility of growth hormone in older men with age-related low testosterone Metabolism, 2017. PMID: 28285644. https://pubmed.ncbi.nlm.nih.gov/28285644/
- Testosterone administration increases insulin-like growth factor-I levels in normal men Journal of Clinical Endocrinology & Metabolism, 1993. PMID: 7690364. https://pubmed.ncbi.nlm.nih.gov/7690364/
- Testosterone and growth hormone improve body composition and muscle performance in older men Journal of Clinical Endocrinology & Metabolism, 2009. PMID: 19293261. https://pubmed.ncbi.nlm.nih.gov/19293261/
- The 2026 Prohibited List: International Standard, section S2.2.4 growth hormone releasing factors World Anti-Doping Agency, 2026. WADA 2026 Prohibited List. https://www.wada-ama.org/en/resources/2026-prohibited-list
